These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3495642)

  • 1. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Clarke CE; Sambrook MA; Mitchell IJ; Crossman AR
    J Neurol Sci; 1987 May; 78(3):273-80. PubMed ID: 3495642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Clarke CE; Boyce S; Sambrook MA; Stahl SM; Crossman AR
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):35-8. PubMed ID: 2907097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of chorea and dystonia in parkinsonian primates.
    Boyce S; Clarke CE; Luquin R; Peggs D; Robertson RG; Mitchell IJ; Sambrook MA; Crossman AR
    Mov Disord; 1990; 5(1):3-7. PubMed ID: 2296255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Clarke CE; Boyce S; Robertson RG; Sambrook MA; Crossman AR
    J Neurol Sci; 1989 May; 90(3):307-14. PubMed ID: 2786926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
    Chen S
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):50-2, 64. PubMed ID: 1591961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Jenner P
    Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
    Konitsiotis S; Blanchet PJ; Verhagen L; Lamers E; Chase TN
    Neurology; 2000 Apr; 54(8):1589-95. PubMed ID: 10762498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
    Cenci MA; Crossman AR
    Mov Disord; 2018 Jul; 33(6):889-899. PubMed ID: 29488257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
    Jenner P
    Neurology; 2003 Sep; 61(6 Suppl 3):S4-11. PubMed ID: 14504374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.
    Page RD; Sambrook MA; Crossman AR
    Neuroscience; 1993 Jul; 55(1):147-65. PubMed ID: 7688878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
    Lieu CA; Deogaonkar M; Bakay RA; Subramanian T
    Parkinsonism Relat Disord; 2011 Jan; 17(1):34-9. PubMed ID: 21074478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
    Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
    Crossman AR; Clarke CE; Boyce S; Robertson RG; Sambrook MA
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):428-35. PubMed ID: 3119180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
    Page RD
    Acta Neurochir (Wien); 1992; 114(3-4):77-117. PubMed ID: 1580197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM; Chase TN
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.